Authors: Bussmann, C.¹; Maintz, L.¹; Hart, J.¹; Allam, J.-P.¹; Vrtala, S.²; Chen, K.-W.²; Bieber, T.³; Thomas, W. R.⁴; Valenta, R.²; Zuberbier, T.⁵; Sager, A.⁶; Novak, N.

Source: Clinical & Experimental Allergy, Volume 37, Number 9, September 2007 , pp. 1277-1285(9)

Publisher: Wiley-Blackwell

Abstract:

Summary Background

House dust mites (HDMs) represent significant indoor allergen sources for patients with atopic dermatitis (AD). Subcutaneous allergen-specific immunotherapy (SCIT) has been shown to be successful in patients with allergic rhinitis and mild asthma and might represent an attractive therapeutic option for the long-term treatment of HDM sensitizations in AD patients. However, only a few studies have been conducted on the effectiveness of HDM SCIT in AD, resulting in controversial clinical results. Data on immunological changes induced by SCIT in AD patients are rare. Objectives

We performed an open pilot study to assess clinical changes and objective laboratory parameters and evaluate the benefit of HDM SCIT in 25 AD patients with IgE-mediated sensitization against HDM. Methods

The severity of AD was evaluated by the severity scoring of atopic dermatitis system (SCORAD). Specific IgE and IgG4 against HDM and serum levels of TARC/CCL17, MDC/CCL22, IL-16, IL-4, IFN-γ, IL-10 and TGF-β1 were measured during SCIT. Results

Subjective and objective SCORAD improved significantly within only 4 weeks of treatment. The level of the tolerogenic cytokine IL-10 increased, whereas CCL17 and IL-16 decreased in the sera of the patients during SCIT. Allergen specific IgE decreased, while IgG4 increased during SCIT. Conclusion

In this open-label pilot study, SCIT with an HDM extract in patients with AD led to a significant improvement of AD mirrored by a reduction of SCORAD as well as serological and immunological changes, which might serve as valuable parameters to estimate the therapeutic effect of SCIT.

Keywords: allergy; atopic dermatitis; house dust mite; specific immunotherapy

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1365-2222.2007.02783.x

Affiliations: 1: Department of Dermatology, University of Bonn, Bonn, Germany, 2: Department of Pathophysiology, Center for Physiology and Pathophysiology, Division of Immunopathology, Medical University of Vienna, Vienna, Austria, 3: Department of Epidemiology, GSF-National Research Center for Enivronment and Health, Neuherberg, Germany 4: Center for Child Health Research, University of Perth, Perth, Australia, 5: Department of Dermatology and Allergy Charité, Allergy Centre Charité, Universitätsmedizin Berlin, Berlin, Germany, 6: Leti Pharma GmbH, Witten, Germany and

Publication date: 2007-09-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Allergy & Immunology
• By this author: Bussmann, C. ;  Maintz, L. ;  Hart, J. ;  Allam, J.-P. ;  Vrtala, S. ;  Chen, K.-W. ;  Bieber, T. ;  Thomas, W. R. ;  Valenta, R. ;  Zuberbier, T. ;  Sager, A. ;  Novak, N.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers